500660 Stock Overview
Manufactures, distributes, and trades in pharmaceuticals in India and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
GlaxoSmithKline Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹2,709.35 |
| 52 Week High | ₹2,825.15 |
| 52 Week Low | ₹1,386.55 |
| Beta | 0.24 |
| 11 Month Change | 3.74% |
| 3 Month Change | 27.04% |
| 1 Year Change | 94.18% |
| 33 Year Change | 68.48% |
| 5 Year Change | 126.02% |
| Change since IPO | 2,203.38% |
Recent News & Updates
Recent updates
Shareholder Returns
| 500660 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 5.4% | 2.2% | -1.0% |
| 1Y | 94.2% | 46.7% | 43.6% |
Return vs Industry: 500660 exceeded the Indian Pharmaceuticals industry which returned 46.7% over the past year.
Return vs Market: 500660 exceeded the Indian Market which returned 43.6% over the past year.
Price Volatility
| 500660 volatility | |
|---|---|
| 500660 Average Weekly Movement | 6.1% |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in IN Market | 9.7% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: 500660's share price has been volatile over the past 3 months.
Volatility Over Time: 500660's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1924 | 3,211 | Bhushan Akshikar | india-pharma.gsk.com |
GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tetanus and pertussis; Fluarix Tetra for the prevention of influenza disease; Varilrix for active immunization against varicella; and Shingrix for prevention of herpes zoster and post-herpetic neuralgia. It also provides specialty medicines comprising NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; and TRELEGY ELLIPTA for treating chronic obstructive pulmonary disease.
GlaxoSmithKline Pharmaceuticals Limited Fundamentals Summary
| 500660 fundamental statistics | |
|---|---|
| Market cap | ₹453.46b |
| Earnings (TTM) | ₹5.90b |
| Revenue (TTM) | ₹34.54b |
77.8x
P/E Ratio13.3x
P/S RatioIs 500660 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 500660 income statement (TTM) | |
|---|---|
| Revenue | ₹34.54b |
| Cost of Revenue | ₹13.55b |
| Gross Profit | ₹20.99b |
| Other Expenses | ₹15.09b |
| Earnings | ₹5.90b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 02, 2024
| Earnings per share (EPS) | 34.83 |
| Gross Margin | 60.76% |
| Net Profit Margin | 17.08% |
| Debt/Equity Ratio | 0% |
How did 500660 perform over the long term?
See historical performance and comparison